Novel Mechanisms in Resolution to Harness Inflammation for Reconstruction
利用炎症进行重建的解决新机制
基本信息
- 批准号:8073173
- 负责人:
- 金额:$ 64.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-17 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryBiomedical EngineeringBone RegenerationCD59 AntigenCell Culture TechniquesCellsCoinCoupledDental CementumDiseaseEngineeringEvaluationEventExhibitsExudateFamilyFibroblastsGoalsHealedHomeostasisHumanImmunosuppressionImmunosuppressive AgentsIn VitroInflammationInflammatoryLesionLeukocytesMediator of activation proteinMedicineMicrofluidicsMiniature SwineMissionMolecularMusNatural regenerationOralOryctolagus cuniculusPathway interactionsPeriodontal DiseasesPeriodontal LigamentPeriodontitisPlacebosProcessPropertyPublic HealthQualifyingResearchResolutionRoleSystemTimeTissue EngineeringTissuesWound Healinganalogbasebonebone losscraniofacialdesignengineering designhealingin vivoindexinginhibitor/antagonistinjuredmeetingsmonocytemultidisciplinaryneutrophilnovelprogramspublic health relevancereconstructionresponseskillstissue regeneration
项目摘要
DESCRIPTION (provided by applicant): This proposal is submitted in response to RFA-DE-09-001 with the overall goal of identifying novel components in the resolution of inflammation that can be used to control local inflammation and accelerate efforts in tissue engineering and regeneration of both diseased and injured oral and craniofacial tissues. Uncontrolled local inflammation underlies many diseases including periodontal disease (PD). We've uncovered novel fundamental pathways in resolution that generate potent specialized local mediators that are both anti-inflammatory and pro-resolving. These new families of local mediators coined resolvins (Rv) provided the first evidence that resolution of acute local inflammation is an active programmed response that enables tissues to return to homeostasis. They also introduced a paradigm shift with a novel concept for treating periodontal disease and other inflammatory diseases. In rabbit periodontitis with inflammation-induced local bone destruction, one resolvin, i.e., resolvin E1 (RvE1), exhibits potent topical actions reducing inflammation, protecting from bone loss and stimulating tissue regeneration. These results are encouraging because they demonstrate that resolvins are agonists of endogenous resolution programs that can be used to control oral inflammation and tissue damage without immune suppression. To meet the objectives for RFA-DE-09-001, a multi-PI multidisciplinary team is assembled with complementary skills with the focused mission of identifying novel mechanisms and components in resolution that can be designed for control of inflammation in craniofacial tissues to stimulate regeneration and enable reconstruction. Five multi-pronged specific aims are proposed among 3 PIs and their labs. These include: 1. The identification of novel endogenous control mechanisms and components in resolution-inflammation; 2. Construction of novel pro-resolving-medicines (NPRM) from resolving leukocyte microparticles (MP); 3. Qualify novel pro-resolving mediators and design-engineered constructs in microfluidics chambers (MC); 4. Establish properties of new resolvins in periodontal systems for oral regeneration and anti-Inflammation; and 5. Evaluate NPRM systems for local delivery of pro-resolving agonists to surgically treated periodontal lesions in vivo. These aims are focused for the systematic selection of ideal 'smart' NPRM constructs for stimulating resolution of oral inflammation and tissue regeneration. The objectives of the proposed studies include advancing the molecular and cellular mechanisms known in natural resolution of inflammation and resolvins in tissue regeneration as well as assembly of novel bioengineering natural template-design strategies targeted for oral inflammation and craniofacial tissue regeneration.
PUBLIC HEALTH RELEVANCE: This research is relevant to public health because excessive inflammation is now recognized to underlie many widely occurring diseases including periodontal disease (PD). Uncontrolled inflammation also hampers efforts in tissue engineering, regeneration and reconstruction. The proposed studies focus on novel pro-resolving mediators that activate resolution of inflammation to control inflammation and tissue regeneration.
描述(申请人提供):本提案是针对RFA-DE-09-001提出的,总体目标是确定炎症消退中可用于控制局部炎症的新成分,并加速组织工程和病变和受伤口腔和颅面组织的再生。失控的局部炎症是许多疾病的基础,包括牙周病(PD)。我们已经发现了解决问题的新的基本途径,这些途径产生了强大的专业本地调解人,既有抗炎作用,也有促进分解的作用。这些新的局部介质家族被称为解决素(RV),这提供了第一个证据,表明急性局部炎症的消解是一种主动的程序性反应,使组织能够恢复内稳态。他们还引入了治疗牙周病和其他炎症性疾病的新概念的范式转变。在炎症诱导的局部骨质破坏的兔牙周炎中,一种解决素,即解决素E1(RvE1),具有有效的局部作用,可减轻炎症,防止骨丢失和刺激组织再生。这些结果令人鼓舞,因为它们表明,分解素是内源性分解程序的激动剂,可用于控制口腔炎症和组织损伤,而不会抑制免疫。为了达到RFA-DE-09-001的目标,组建了一个多PI多学科团队,他们的技能互补,重点任务是确定新的机制和组件,这些机制和组件可以设计用于控制头面部组织的炎症,以刺激再生和实现重建。在3个绩效指标及其实验室中,提出了5个多管齐下的具体目标。这些包括:1.识别新的内源性控制机制和分解炎症的成分;2.从白细胞微粒(MP)中构建新的分解前药物(NPRM);3.在微流体室(MC)中鉴定新的分解前介质和设计的结构;4.建立牙周系统中用于口腔再生和抗炎的新的分解素的性质;以及5.评价NPRM系统用于将促进分解的激动剂局部输送到手术治疗的活体牙周病变中。这些目的是为了系统地选择理想的“智能”NPRM结构,以刺激口腔炎症的消退和组织再生。拟议研究的目标包括推进已知的自然消炎的分子和细胞机制以及组织再生中的消解素,以及针对口腔炎症和颅面组织再生的新型生物工程天然模板设计策略的组装。
公共卫生相关性:这项研究与公共健康相关,因为过度炎症现在被认为是许多广泛发生的疾病的基础,包括牙周病(PD)。不受控制的炎症也阻碍了组织工程、再生和重建的努力。拟议的研究集中在新型促分解介质上,这些介质可以激活炎症的分解来控制炎症和组织再生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Irimia其他文献
Daniel Irimia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Irimia', 18)}}的其他基金
In vivo Monitoring of Neutrophil Function in Patients after Stem Cell Transplant
干细胞移植后患者中性粒细胞功能的体内监测
- 批准号:
10679553 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
Microfluidic Assays for Probing Neutrophil-Borrelia Interactions in Blood during Acute Lyme Disease
用于探测急性莱姆病期间血液中中性粒细胞与疏螺旋体相互作用的微流控分析
- 批准号:
10379279 - 财政年份:2021
- 资助金额:
$ 64.35万 - 项目类别:
Microfluidic Assessment of Clinical Outcomes in Preterm Newborns
早产儿临床结果的微流控评估
- 批准号:
10164831 - 财政年份:2017
- 资助金额:
$ 64.35万 - 项目类别:
Transient Obstruction of Capillary Networks by Chromatin Yarns from Neutrophils in Older Adults
老年人中性粒细胞染色质纱线对毛细血管网络的短暂阻塞
- 批准号:
8953369 - 财政年份:2015
- 资助金额:
$ 64.35万 - 项目类别:
Microfluidic tools for probing neutrophil reversed migration
用于探测中性粒细胞反向迁移的微流体工具
- 批准号:
9096701 - 财政年份:2015
- 资助金额:
$ 64.35万 - 项目类别:
Neutrophil Decision Making in Confined Environments in Health and Disease
健康和疾病中受限环境中的中性粒细胞决策
- 批准号:
9897528 - 财政年份:2010
- 资助金额:
$ 64.35万 - 项目类别:
Neutrophil Decision Making in Confined Environments in Health and Disease
健康和疾病中受限环境中的中性粒细胞决策
- 批准号:
10379440 - 财政年份:2010
- 资助金额:
$ 64.35万 - 项目类别:
Neutrophil Decision Making in Confined Environments in Health and Disease
健康和疾病中受限环境中的中性粒细胞决策
- 批准号:
7859917 - 财政年份:2010
- 资助金额:
$ 64.35万 - 项目类别:
Neutrophil Decision Making in Confined Environments in Health and Disease
健康和疾病中受限环境中的中性粒细胞决策
- 批准号:
8068338 - 财政年份:2010
- 资助金额:
$ 64.35万 - 项目类别:
Neutrophil Decision Making in Confined Environments in Health and Disease
健康和疾病中受限环境中的中性粒细胞决策
- 批准号:
8463563 - 财政年份:2010
- 资助金额:
$ 64.35万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 64.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 64.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 64.35万 - 项目类别: